If you've wondered why your GLP-1 starts at a dose that barely does anything, that's by design. Titration — the deliberate, stepwise climb to your target dose — exists mostly to keep side effects manageable, and understanding its logic makes the whole first stretch of treatment less confusing.
Why doses start low and climb gradually
Every approved GLP-1 medication uses a titration schedule — starting well below the eventual target dose and increasing in steps, typically every few weeks. This isn't about "easing you in" for comfort's sake alone; the low starting doses are generally below the threshold needed for meaningful blood sugar or weight effects. The primary purpose of titration is tolerability: giving your digestive system time to adjust to slowed gastric emptying (see our glossary entry on satiation) before increasing the dose further, since jumping straight to a target dose produces significantly more severe GI side effects for most people.
The general pattern across GLP-1 medications
Titration schedules vary by specific drug, but they generally follow the same shape: a low, sub-therapeutic starting dose held for a set period (commonly around 4 weeks, though some drugs use shorter or weekly increments), followed by step increases at set intervals until reaching either a target maintenance dose or the maximum tolerated dose. Exact doses, increments, and timing differ meaningfully between drugs — always follow your specific prescribed schedule and confirm details with your prescriber or pharmacist rather than assuming one drug's schedule applies to another.
Why the schedule matters for side effects
Our guide on the GLP-1 side effect timeline covers how side effects cluster predictably around each dose increase — this is a direct consequence of the titration structure. Side effects that spike after an increase and then ease before the next step are generally expected; a schedule that's being followed faster than recommended (including restarting after a gap at your prior dose rather than re-titrating) is a specific, documented risk factor for more severe symptoms, including in more serious cases.